Development of a Clinician-reported Screening Tool to Identify Patients with Parkinson’s disease inadequately controlled on oral medications
Objective: To identify key clinical indicators for Parkinson disease (PD) patients inadequately controlled with oral medications or eligible for device-aided treatments. Background: Identifying patients with…Specific Bdnf variants are associated with suboptimal response to levodopa but not to other dopaminergic medications or deep brain stimulation in Parkinson’s disease
Objective: We examined the impact of rs6265 and other brain-derived neurotrophic factor (Bdnf) variants in two subject cohorts: 1) early-stage Parkinson’s disease (PD) subjects from…Risk of Parkinson’s disease in zolpidem user: A systematic review and meta-analysis
Objective: To explore the association between zolpidem use and risk of Parkinson's disorder. Background: Zolpidem is commonly prescribed for the treatment of sleep disorder. Epidemiological…Treatment of Parkinson’s disease psychosis–a systematic review of RCTs
Objective: An SLR was conducted to assess the evidence from RCTs supporting the safety and efficacy of Parkinson’s disease psychosis (PDP) treatments. Background: PDP is…Huntington’s Disease Regulatory Science Consortium (HD-RSC): Enabling Pathways to Effective Treatments Through Regulatory Science and Innovation
Objective: To establish a broad-based consortium, the Huntington’s Disease Regulatory Science Consortium (HD-RSC), which will advance disease specific data standards and drug development tools, as…Levodopa responsiveness in Parkinson’s disease is significantly impaired in those with diabetes and increased vascular risk.
Objective: To define variation in L-dopa response in recent onset PD. Background: L-Dopa responsiveness is a defining feature of Parkinson’s disease (PD), but the degree…Effect of Pridopidine on Total Functional Capacity (TFC) in Huntington Disease (HD): Results of a Cohort Comparison of Open-HART and Historical Placebo Subjects
Objective: To measure functional decline by TFC change in HD patients treated with open-label pridopidine at 45 mg BID (Open-HART) for 36 months (mos), and…Incorporating Specialist Independent Prescribing Pharmacist (SIPP) sessions into the Movement Disorder Service
Objective: To describe the incorporation of a prescribing pharmacist into a Multi-disciplinary Parkinson's clinic based in a University Hospital Background: Evidence shows that a multidisciplinary…Implementation and Validation of a Biometric Solution for Remote Monitoring of Motor Symptoms in Patients with Huntington Disease in a Phase II Clinical Trial
Objective: To implement and validate quantification of motor dysfunction in a Huntington disease (HD) clinical trial using machine learning algorithmic analysis derived from biometric monitoring…The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
Objective: The levodopa tablet is prone to dissolve in acidic conditions. We investigated whether gastric acid suppressants (histamine-2 receptor antagonists or proton pump inhibitors) and…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 32
- Next Page »